Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:04:35.090Z.
Calculation as of: 2026-10-06T16:04:35.090Z.
Quote observation: 2026-10-06T16:00:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f7eba9f13d95fb6821c25c67f521ed103bec1ea18c2b869fb2c3b9acf85efa0e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$12.91M
PS Ratio
N/A
TTM Avg
47196.93
3Y Avg
20633.59
5Y Avg
21825.74
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Passage Bio, Inc. (PASG) | $12.92M | N/A | N/A | N/A | N/A |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.91M | N/A | 47196.93 | 20633.59 | 21825.74 |
| Lantern Pharma Inc. (LTRN)vs › | $12.71M | N/A | N/A | N/A | N/A |
| IRIDEX Corporation (IRIX)vs › | $12.63M | 0.24 | 0.35 | 0.52 | 0.71 |
| Cytosorbents Corporation (CTSO)vs › | $12.60M | 0.34 | 0.98 | 1.40 | 2.22 |
| Optimi Health Corp. (OPTH)vs › | $13.27M | 106.77 | 130.06 | 643.92 | 552.45 |
| Dare Bioscience, Inc. (DARE)vs › | $12.54M | 9.18 | 21.58 | 247.97 | 174.73 |
| IN8bio, Inc. (INAB)vs › | $13.71M | N/A | N/A | N/A | N/A |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $13.90M | 1.96 | 3.04 | 3.04 | 3.04 |
| Vyome Holdings, Inc. (HIND)vs › | $13.97M | 107.67 | 20.09 | 7.30 | 5.50 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-03 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-12 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-10 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
